(2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digit Health, 4, e873-e883. http://doi.org/10.1016/s2589-7500(22)00174-1.
*Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
(2022). Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. Bmc Endocr Disord, 22, 241. http://doi.org/10.1186/s12902-022-01140-1.
(2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437.
(2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75-85. http://doi.org/10.1111/dom.14189.